Sustained-release isosorbide-5-mononitrate improves exercise capacity 30 minutes after oral application

Clinical Drug Investigation

Volumn 14, Issue 2, 1997, Pages 117-124

  Guzik, J ^a   Kanopka, M ^a   Maciejewicz, J ^a   Maziarz, A ^a   Stepien, J ^a  

^a Dietl Hospital   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ISOSORBIDE 5 NITRATE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG CAPSULE; DRUG EFFICACY; ERGOMETRY; EXERCISE; EXERCISE TEST; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE PREPARATION; TIME;

EID: 0030879853     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199714020-00005     Document Type: Article

References (16)

1. Bonn R. Sustained release isosorhide mononitrate (50 mg): optimisation of a once-daily dosage form for long-term treatment of angina pectoris. Am J Cardiol 1988; 61: 12E-14E
2. Ahmadinejad M, Eghbal B, Sorgenicht W, et al. Slow-release isosorbide-5-mononitrate - a new once-daily therapeutic modality for angina pectoris. Eur Heart J 1988; 9 Suppl. A: 135-9
3. Beyerle A, Reiniger G, Rudolph W. Long-acting, marked antiischemic effect maintained unattenuated during long-term interval treatment with once-daily isosorbide-5-mononitrate in sustained-release form. Am J Cardiol 1990; 65: 1434-7
4. Jansen W, Prenzel R, Kümper H, et al. Interval treatment of coronary artery disease with sustained-release isosorbide-5-mononitrate. Am J Cardiol 1990; 65: 16J-22J
5. Heepe W, Gathmann-Lewik U. Antianginal efficacy and tolerability of 50mg sustained-release isosorbide-5-mononitrate in an open twelve-months observation study. Cardiology 1987; 74 Suppl. 1: 34-9
6. Kenedi P, Gathmann-Lewik U. Dose-effect relationship amongst three different sustained-release forms of isosorbide-5-mononitrate in patients with coronary artery disease. Cardiology 1987; 74 Suppl. 1: 29-33
7. Ingendaay A, Klein G, Rehm D, et al. A comparison of the pharmacokinetics of different sustained-release mononitrate presentations. Münch Med Wochenschr 1987; 3: 34-6
8. Bussmann WD. Comparison of the nitrate patch Biophase 10 with placebo and 20mg isosorbide-5-nitrate (Elantan® 20) in aspect of anti-ischaemic efficacy and onset of action in a short-term study. Study report F 8328, 1991, Schwarz Pharma AG
9. Eggeling TH, Jansen W, Osterspey A, et al. Einfluß von 50 mg Isosorbid-5-Nitrat retard auf die Belastbarkeit von Patienten mit koronarer Herzkrankheit. Med Klin 1986; 81 (8): 275-80
10. Grizzle JE. The two period change-over design and its use in clinical trials. Biometrics 1965; 5: 467-80
11. Jones B, Kenward MG. Design and analysis of cross-over trials. London: Chapman and Hall, 1989
12. Abrams J. Tolerance to organic nitrates. Circulation 1986; 74 (6): 1181-5
13. Luke R, Sharpe N, Coxon R. Transdermal nitroglycerin in angina pectoris: efficacy of intermittent application. J Am Coll Cardiol 1987; 10 (3): 642-6
14. Goldberg R, Brady P, James EM, et al. Time of onset of symptoms of acute myocardial infarction. Am J Cardiol 1990; 66: 140-4
15. Rocco MB, Barry J, Campbell S, et al. Circadian variation of transient myocardial ischemia in patients with coronary artery disease. Circulation 1987; 75: 395-400
16. Willich SN, Loewel H, Lewis M, et al. Association of wake time and the onset of myocardial infarction. Circulation 1991; 80 Suppl. VI: V162-VI-7